Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus tislelizumab as neoadjuvant therapy for cisplatin-intolerant muscle-invasive bladder urothelial carcinoma
ChiCTR2400086194Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib and tislelizumab in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Dose-limiting toxicity. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
palbociclibtislelizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2400086194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086194.